Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy
| Status: | Recruiting |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 2/16/2018 |
| Start Date: | March 2015 |
| End Date: | December 2021 |
| Contact: | Linda Cendales, MD |
| Email: | linda.cendales@duke.edu |
| Phone: | 919-681-7514 |
The purpose of this study is to determine the safety and efficacy of hand transplantation as
a treatment for patients with loss of limb below the elbow, The study will focus on patients
who have had loss of limb. The primary endpoint is the ability to use the tranplanted limb in
activities of daily living at 18 months following transplantation measured by a quantitative
functional test.
Study activities include several study visits over 18 months and include; demographics,
medical history, vital signs, psychosocial evaluation, urine, blood test, chest x-ray, bone
density scans, and biopsies. Subjects who are 18-65 and willing to travel to site and have
loss of limb will be included in study evaluation.
Risks of the study include risk of rejection and infection after being transplanted.
Additional risk are associated with procedures that include blood draws, biopsies, x-rays,
and potential loss of confidentiality. All patient data will be kept electronically and in
accordance with the requirements of Duke University. In addition to the experimental data,
this database includes recipient and donor demographics and transplant relevant medical
history, range of motion, sensation, and immunosuppressive medications. Data will be recorded
and reported in accordance with the standards required by the United Network for Organ
Sharing (UNOS).
a treatment for patients with loss of limb below the elbow, The study will focus on patients
who have had loss of limb. The primary endpoint is the ability to use the tranplanted limb in
activities of daily living at 18 months following transplantation measured by a quantitative
functional test.
Study activities include several study visits over 18 months and include; demographics,
medical history, vital signs, psychosocial evaluation, urine, blood test, chest x-ray, bone
density scans, and biopsies. Subjects who are 18-65 and willing to travel to site and have
loss of limb will be included in study evaluation.
Risks of the study include risk of rejection and infection after being transplanted.
Additional risk are associated with procedures that include blood draws, biopsies, x-rays,
and potential loss of confidentiality. All patient data will be kept electronically and in
accordance with the requirements of Duke University. In addition to the experimental data,
this database includes recipient and donor demographics and transplant relevant medical
history, range of motion, sensation, and immunosuppressive medications. Data will be recorded
and reported in accordance with the standards required by the United Network for Organ
Sharing (UNOS).
Inclusion Criteria:
1. Patients from 18-65 years old with loss of limb
2. Willingness and legal ability to give informed consent
3. Willingness to travel to study site for protocol specific samples to be taken, or in
some cases, the ability to send samples via overnight mail
Exclusion Criteria:
- Any condition that precludes serial follow-up
- Any condition that would likely increase the risk of protocol participation or
confound the interpretation of the data
- Any active malignancy or any history of a malignancy or lymphoma
- Inability or unwillingness to comply with protocol monitoring and therapy and
immunodeficiency syndrome(s)
We found this trial at
1
site
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
